mulethi

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• acne [Insufficient Evidence]
• Addison dz [Insufficient Evidence]
• adrenal insufficiency [Insufficient Evidence]
• allergic rhinitis [Insufficient Evidence]
• aphthous ulcer (canker sores) [Possibly Effective]
• atopic dermatitis (eczema) [Possibly Effective]
• bleeding [Insufficient Evidence]
• cancer-related pain [Insufficient Evidence]
• chronic fatigue syndrome [Insufficient Evidence]
• colic [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• dental caries prevention [Insufficient Evidence]
• dental plaque [Insufficient Evidence]
• depression [Insufficient Evidence]
• diabetes [Insufficient Evidence]
• dysmenorrhea [Insufficient Evidence]
• dyspepsia [Insufficient Evidence]
• endotracheal intubation-related adverse effects [Possibly Effective]
• familial Mediterranean fever (FMF) [Insufficient Evidence]
• hepatitis [Insufficient Evidence]
• H. pylori infection [Insufficient Evidence]
• hypercholesterolemia [Insufficient Evidence]
• hyperkalemia [Insufficient Evidence]
• hyperprolactinemia, antipsychotic-induced [Insufficient Evidence]
• IgA vasculitis [Insufficient Evidence]
• IBS [Insufficient Evidence]
• lichen planus [Insufficient Evidence]
• liver CA [Insufficient Evidence]
• melasma [Insufficient Evidence]
• menopausal sx [Insufficient Evidence]
• muscle cramps [Insufficient Evidence]
• nonalcoholic fatty liver dz [Insufficient Evidence]
• obesity [Insufficient Evidence]
• oral mucositis, chemo- or XRT-related [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• osteoporosis [Insufficient Evidence]
• Parkinson dz [Insufficient Evidence]
• peptic ulcer [Insufficient Evidence]
• physical performance [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• prostate CA [Insufficient Evidence]
• psoriasis [Insufficient Evidence]
• SLE [Insufficient Evidence]
• tuberculosis [Insufficient Evidence]
• urticaria [Insufficient Evidence]
• vitiligo [Insufficient Evidence]
• xerostomia [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]

Info: products generally stdzd to glycyrrhizin content

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

allergic rhinitis

[Insufficient Evidence]

Dose: 3 mg/mL intranasally qd; Info: nasal irrigation suspension containing 900 mg licorice extract powder and 3 g iodine-free salt in 300 mL warm water

aphthous ulcer (canker sores)

[Possibly Effective]

Dose: apply 0.015-0.229 mg/kg patch topically qd x16 h/day; Alt: apply 1% patch topically qd; 3 mL (5% licorice extract solution plus diphenhydramine) swish/spit qid; 200 mg deglycyrrhizinated licorice powder/200 mL warm water swish/spit qid

atopic dermatitis (eczema)

[Possibly Effective]

Dose: apply 1-2% gel topically tid

bleeding

[Insufficient Evidence]

Dose: apply 0.09 mg/1 mL spray topically x4; Info: used in episiotomy repair and dental procedures

COVID-19

[Insufficient Evidence]

Dose: 300 mg PO qd; Info: used w/ boswellia and standard tx

dental caries prevention

[Insufficient Evidence]

Dose: 15 mL (1% solution) swish/spit qhs

depression

[Insufficient Evidence]

Dose: 1400 mg PO qd; Info: used w/ standard tx

dysmenorrhea

[Insufficient Evidence]

Dose: 750 mg PO bid on days 1-5 of menstrual cycle

dyspepsia

[Insufficient Evidence]

Dose: 33.3 mg/1 mL licorice root extract PO tid

endotracheal intubation-related adverse effects

[Possibly Effective]

Dose: 97 mg lozenge PO x1 given 30min before intubation; Alt: 0.5 g solution swish/spit x1 given 5min before intubation

H. pylori infection

[Insufficient Evidence]

Dose: 380 mg PO bid; Alt: 100 mg PO qd; Info: used w/ or w/o standard tx

hypercholesterolemia

[Insufficient Evidence]

Dose: 100 mg PO qd

hyperkalemia

[Insufficient Evidence]

Dose: 150 mg PO qd; Alt: 1 g PO qd

IgA vasculitis

[Insufficient Evidence]

Dose: 25 mg compound glycyrrhizin PO tid in pts 12 yo and younger; 50 mg compound glycyrrhizin PO tid in pts >12 yo; Info: products containing glycyrrhizin, glycine and methionine; used w/ conventional tx

lichen planus

[Insufficient Evidence]

Dose: 40 mL (0.2% glycyrrhizin) IV qd x4wk

melasma

[Insufficient Evidence]

Dose: apply 7% cream topically bid

menopausal sx

[Insufficient Evidence]

Dose: 330 mg PO tid

nonalcoholic fatty liver dz

[Insufficient Evidence]

Dose: 2 g PO qd; Alt: 0.5 g PO bid

oral mucositis, chemo- or XRT-related

[Insufficient Evidence]

Dose: apply paste (5 g powder mixed in honey) topically bid plus 500 mg PO bid; Alt: apply film topically qid; Info: used w/ standard tx

Parkinson dz

[Insufficient Evidence]

Dose: 136 mg PO bid

peptic ulcer

[Insufficient Evidence]

Dose: 2.28-4.56 g deglycyrrhizinated licorice/day PO divided tid

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 2.25 g PO qd

psoriasis

[Insufficient Evidence]

Dose: apply cream topically bid; Info: used w/ corticosteroid cream

urticaria

[Insufficient Evidence]

Dose: 50-75 mg compound glycyrrhizin PO tid; Info: products containing glycyrrhizin, N-acetyl cysteine and glycine

vitiligo

[Insufficient Evidence]

Dose: 25-75 mg compound glycyrrhizin PO tid; Info: used w/ standard tx